Cite
MLA Citation
S. Kondo et al.. “314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer.” European journal of cancer, vol. 51, n.d., pp. S59–. http://access.bl.uk/ark:/81055/vdc_100030627995.0x00004b